Literature DB >> 16095459

Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions.

V G Nielsen1.   

Abstract

Colloid-mediated hypocoagulability is clinically important, but the mechanisms responsible for coagulopathy have been incompletely defined. Thus, my goal was to elucidate how colloids decrease plasma coagulation function. Plasma was diluted 0% or 40% with 0.9% NaCl, three different hydroxyethyl starches (HES, mean molecular weight 450, 220 or 130 kDa), or 5% human albumin. Samples (n=6 per condition) were activated with celite, and diluted samples had either no additions or addition of fibrinogen (FI), thrombin (FIIa) or activated Factor XIII (FXIIIa) to restore protein function to prediluted values. Thrombelastographic variables measured included clot propagation (angle, alpha), and clot strength (amplitude, A; or shear elastic modulus, G). Dilution with 0.9% NaCl significantly decreased alpha, A and G-values compared to undiluted samples. Supplementation with FI, but not FIIa or FXIIIa, resulted in 0.9% NaCl-diluted thrombelastographic variable values not different from those of undiluted samples. FI supplementation of HES 450, HES 220, HES 130 and albumin-diluted samples only partially restored alpha, A and G-values compared to undiluted samples. FIIa addition only improved clot propagation and strength in albumin-diluted samples. FXIIIa supplementation improved propagation in samples diluted with HES 450, HES 220 and albumin, and clot strength improved in HES 450 and albumin-diluted plasma. Considered as a whole, these data support compromise of FIIa-FI and FXIIIa--fibrin polymer interactions as the mechanisms by which colloids compromise plasma coagulation. Investigation to determine if clinical enhancement of FXIII activity and/or FI concentration (e.g. fresh-frozen plasma, cryoprecipitate) can attenuate colloid-mediated decreases in hemostasis is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16095459     DOI: 10.1111/j.1399-6576.2005.00733.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  20 in total

1.  The influence of coagulation and inflammation research on the improvement of polytrauma care.

Authors:  M Perl; M Huber-Lang; F Gebhard
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-09       Impact factor: 3.693

2.  Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.

Authors:  Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

Review 3.  Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis.

Authors:  Amit Patel; Umeer Waheed; Stephen J Brett
Journal:  Intensive Care Med       Date:  2013-02-22       Impact factor: 17.440

Review 4.  Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review.

Authors:  Christiane S Hartog; Dorit Reuter; Wolfgang Loesche; Michael Hofmann; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2011-10-12       Impact factor: 17.440

Review 5.  Coagulation management in multiple trauma: a systematic review.

Authors:  Heiko Lier; Bernd W Böttiger; Jochen Hinkelbein; Henning Krep; Michael Bernhard
Journal:  Intensive Care Med       Date:  2011-02-12       Impact factor: 17.440

6.  The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro.

Authors:  Christoph Johannes Schlimp; Janne Cadamuro; Cristina Solomon; Heinz Redl; Herbert Schöchl
Journal:  Blood Transfus       Date:  2012-12-13       Impact factor: 3.443

7.  HES 130/0.4 impairs haemostasis and stimulates pro-inflammatory blood platelet function.

Authors:  Maik Sossdorf; Sascha Marx; Barbara Schaarschmidt; Gordon P Otto; Ralf A Claus; Konrad Reinhart; Christiane S Hartog; Wolfgang Lösche
Journal:  Crit Care       Date:  2009-12-22       Impact factor: 9.097

Review 8.  Fibrinogen concentrate in bleeding patients.

Authors:  Anne Wikkelsø; Jens Lunde; Mathias Johansen; Jakob Stensballe; Jørn Wetterslev; Ann Merete Møller; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2013-08-29

9.  Activated clotting time of thrombelastography (T-ACT) predicts early postinjury blood component transfusion beyond plasma.

Authors:  Hunter B Moore; Ernest E Moore; Theresa L Chin; Eduardo Gonzalez; Michael P Chapman; Carson B Walker; Angela Sauaia; Anirban Banerjee
Journal:  Surgery       Date:  2014-06-02       Impact factor: 3.982

Review 10.  Current management of massive hemorrhage in trauma.

Authors:  Pär I Johansson; Jakob Stensballe; Sisse R Ostrowski
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-07-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.